Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and ≤106/kg T cells may have an adverse effect on transplant-related mortality

Annals of Hematology

Volumn 84, Issue 5, 2005, Pages 331-338

  Hartwig, Udo F ^a   Winkelmann, Nils ^a   Wehler, Thomas ^a   Kreiter, Sebastian ^a   Schneider, Peter M ^a   Meyer, Ralf G ^a   Ullmann, Andrew J ^a   Huber, Christoph ^a   Kolbe, Karin ^a   Herr, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Allogeneic stem cell transplantation; CD34 selection; Opportunistic infection; Reduced intensity conditioning; T cell depletion

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; ITRACONAZOLE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; ALKYLATING AGENT; CD34 ANTIGEN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; VIDARABINE;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CD34 SELECTION; CHIMERA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TOLERABILITY; EX VIVO STUDY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES; HIGH RISK PATIENT; HLA MATCHING; HUMAN; KIDNEY FAILURE; LIVING DONOR; MALE; MORBIDITY; MORTALITY; MYCOSIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PILOT STUDY; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RISK ASSESSMENT; RISK FACTOR; T CELL DEPLETION; VIRUS REACTIVATION; ALLOTRANSPLANTATION; BACTERIAL PNEUMONIA; BLOOD DISEASE; CELL FRACTIONATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MICROBIOLOGY; MIDDLE AGED; T LYMPHOCYTE; TRANSPLANTATION;

ADULT; ANTIGENS, CD34; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL FRACTIONATION; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MELPHALAN; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMONIA, BACTERIAL; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 23244431995     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-1001-5     Document Type: Article

References (46)

1. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J (1998) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671-3680 9573003
2. Bacigalupo A (2000) Second EBMT workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 29:191-195
3. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midoll Osseo (GITMO). Blood 98:2942-2947
4. Baron F, Siquet J, Schaaf-Lafontaine N, Baudoux E, Hermanne JP, Fillet G, Beguin Y (2002) Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica 87:78-88
5. Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM (1996) The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 45:29-32
6. Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podesta M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A (1998) Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 83:904-909
7. Charkrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 99:4357-4363
8. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071-1078
9. Childs R, Clave E, Contentin N, Javasekra D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234-3241 1:CAS:528:DyaK1MXntVSrtLs%3D
10. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barett AJ (1996) Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 18:347-353
11. Craddock C, Bardy P, Kreiter S, Johnston R, Apperley J, Marks D, Huber C, Kolbe K, Goulding R, Lawler M, Goldman J, Hughes T, Derigs G (2000) Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol 111:797-800
12. Dazzi F, Szydlo RM, Goldman JM (1999) Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand. Exp Hematol 10:1477-1486
13. Fagioli F, Ricchiardi A, Carnevale-Schianca F (2002) Non-myeloablative allogeneic hematopoietic stem cell transplants. Haematologica 87 [8 Suppl]:13-19
14. JLM Ferrera JH Antin 1999 Pathophysiology of graft-versus-host disease In: ED Thomas KG Blume SJ Forman (eds) Hematopoietic stem cell transplantation Blackwell Scientific Publications Boston, MA 305-315
15. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I (1995) CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337-4343
16. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536 1:CAS:528:DyaK2sXjvFCkt7g%3D
17. Goerner M, Kordelas L, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F, Punzel M, Weber-Nordt R, Moos M, Goldschmidt H, Ho AD (2002) Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine. Bone Marrow Transplant 29:621-624
18. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806-814 1:STN:280:BieB38%2FoslU%3D
19. Ho VT, Soiffer RJ (2001) The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98:3192-3204
20. Ho AYL, Kenyon M, El-Hemaidi I, Devereux S, Pagliuca A, Mufti GJ (2003) Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: Survival does not plateau until after day 200. Blood 101:779-780
21. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562 1:STN:280:By%2BC38zhs1w%3D
22. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Malech HL (2001) Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 344:881-888
23. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R (1998) Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonmyeloablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment of lymphoid malignancies. J Clin Oncol 18:2817-2824
24. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465 1:STN:280:By6D1M7kvVc%3D
25. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425
26. Kreiter S, Winkelmann N, Schneider PM, Schuler M, Fischer T, Ullmann AJ, Huber C, Derigs HG, Kolbe K (2001) Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 28:157-161
27. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C (2003) Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: An EBMT megafile analysis. Blood 102:4255-4260
28. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, Leblond V, Michallet M, Dreyfus F, Ifrah N (1987) Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2:175-178 10.1016/S0140-6736(87)90763-X
29. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP (1985) Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 3:664-672
30. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400 10.1182/blood.V97.11.3390
31. 5Nash RA, Storb R (1996) Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr Opin Immunol 8:674-680
32. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Ponisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with haematological diseases. Blood 101:1620-1629 10.1182/blood-2002-05-1340
33. Passweg JR, Meyer-Monard S, Gregor M, Favre G, Heim D, Ebnoether M, Tichelli A, Gratwohl A (2002) High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 30:267-271
34. Popplewell LL, Forman SJ (2002) Is there an upper age limit for bone marrow transplantation? Bone Marrow Transplant 29:277-284
35. Prentice HG, Blacklock HA, Janossy G, Gilmore MJ, Price-Jones L, Tidman N, Trejdosiewicz LK, Skeggs DB, Panjwani D, Ball S (1984) Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 3:472-476
36. Schetelig J, Kröger N, Held TK, Thiede C, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhauser M, Ehninger G, Zander AR, Siegert W (2002) Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 87:299-305
37. Schneider PM, Kreiter S et al (2003) Quantification of fluorescent STR genotyping results for chimerism control after bone marrow transplantation. In: Brinkmann B, Carracedo A (eds) Prog. Forensic Genetics, 9 Int. Congress Series 1239. Elsevier, Amsterdam, pp 653-656
38. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R (1995) Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 14:1553-1562
39. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic disease. Blood 91:756-763 1:STN:280:DyaK1c7hvVWrtQ%3D%3D
40. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, McSweeney P, Leisenring W, Schulman H (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048-3054 1:CAS:528:DyaK2sXisFCmu7c%3D
41. Sykes M, Preffer F, McAfee S, Seidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR (1999) Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 353:1755-1759 10.1016/S0140-6736(98)11135-2
42. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD (1975) Bone marrow transplantation. N Engl J Med 292:895-902 1:STN:280:CSqC3MfotVQ%3D
43. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, Certoux JM, Robinet E, Saas P, Petracca B, Juttner C, Reynolds CW, Longo DL, Herve P, Cahn JY (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97:63-72
44. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, Perez-Oteiza J, Ferra C, Zuazu J, Caballero D, Carvalhais A, Diez JL, Espigado I, Martinez C, Campilho F, Sanz MA, Sierra J, Garcia-Conde J, Montserrat E, Spanish Group for Allogenic Peripheral Blood Transplantation (2001) The number of CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 97:383-387
45. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, Perez-Oteyza J, Ferra C, Zuazu J, Caballero D, Bargay J, Carvalhais A, Diez JL, Espigado I, Alegre A, Rovira M, Campilho F, Odriozola J, Sanz MA, Sierra J, Garcia-Conde J, Montserrat E, Spanish Group for Allogeneic Peripheral Blood Transplantation (Grupo Espanol de Trasplante Hemopoyetico) and Instituto Portugues de Oncologia-Porto (2002) Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 100:724-727
46. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068-1073 1:STN:280:CSaC2MnmvVQ%3D